AI Agent Operational Lift for Fortrea in Lake Park, North Carolina

Why AI matters at this scale

Fortrea, as a large-scale (10,000+ employee) global contract research organization (CRO) in biotechnology, operates at the critical intersection of life sciences, complex data, and rigorous regulation. The company manages the entire clinical trial lifecycle for pharmaceutical sponsors, from design and site activation to monitoring, data management, and regulatory submission. At this enterprise magnitude, inefficiencies are amplified across hundreds of concurrent trials involving thousands of patients and sites worldwide. Manual processes, data silos, and reactive problem-solving lead to costly delays, with the average drug development program exceeding $2 billion. AI presents a transformative lever to instill predictive intelligence, automate labor-intensive tasks, and derive insights from the petabytes of structured and unstructured data generated across the clinical continuum. For a player of Fortrea's size, adopting AI is not merely an innovation but a strategic imperative to maintain competitive advantage, improve margins, and deliver faster, more reliable outcomes for clients.

Concrete AI Opportunities with ROI Framing

1. AI-Driven Patient Recruitment & Matching: The single greatest bottleneck in clinical development is patient enrollment, which can consume over 30% of the trial timeline. AI algorithms can process electronic health records, genetic databases, and patient registries to identify potential participants who match complex, multi-faceted eligibility criteria. This moves recruitment from a manual, site-led outreach model to a targeted, data-driven campaign. The ROI is direct: reducing enrollment time by just 20% can save sponsors tens of millions per trial and get life-saving therapies to market sooner.

2. Predictive Analytics for Trial Operations: Machine learning models can analyze historical data on site performance, investigator experience, and local healthcare landscapes to predict which trial sites will enroll quickly and maintain high data quality. This enables proactive resource allocation and support, minimizing costly site failures. Furthermore, AI can forecast patient dropout risk based on early indicators, allowing for preemptive retention interventions. The impact is operational excellence: higher-quality data, fewer protocol deviations, and more predictable timelines, translating into stronger client partnerships and repeat business.

3. Intelligent Document Automation and Review: Clinical development is document-intensive, governed by strict regulatory standards. Natural Language Processing (NLP) can automate the drafting of routine clinical study reports, protocols, and informed consent forms by pulling from templates and previous submissions. More advanced AI can review these documents for consistency, completeness, and compliance with regulatory guidelines. This reduces the burden on medical writers and quality assurance staff, cutting document preparation time significantly and mitigating the risk of submission delays due to human error.

Deployment Risks Specific to Large Enterprises

For an organization of Fortrea's size, the primary AI deployment risks are not technological but organizational and regulatory. Integration Complexity: Legacy systems (e.g., clinical data management, safety databases) are often disparate and not built for real-time AI ingestion, requiring significant middleware and data engineering investment. Change Management: Rolling out AI tools across a global, 10,000+ person workforce requires extensive training and may face resistance from teams accustomed to established workflows. Regulatory Scrutiny: Any AI tool touching clinical data or decision-making falls under the purview of health authorities like the FDA. Demonstrating validation, explainability, and consistent performance across diverse populations is a non-negotiable but resource-intensive requirement. A failed AI pilot that attracts regulatory concern could damage client trust. Therefore, a phased, use-case-specific approach with early and deep engagement from Legal, Compliance, and Quality functions is essential to navigate these risks successfully.